Now Enrolling
Burgundy BP41670 – Genentech [Enrollment Open]
A Three-part, Phase I Study To Investigate The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Zifibancimig Following Intravitreal Administration Of Multiple Ascending Doses And Continuous Delivery From The Port Delivery In Patients With Neovascular Age-related Macular Degeneration.
Atmosphere – RGX-314-2104 – REGENXBIO [Enrollment Open]
A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD
Lugano – Eyepoint [Enrollment Open]
A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, A Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects with Wet AMD
Rioja – Eyebio [Enrollment Open]
A phase 1/2a 2-part study consisting of an open-label multiple ascending dose (MAD) safety study in participants with macular edema following branch retinal vein occlusion (BRVO), and a dose-finding, double-masked, comparative safety and preliminary efficacy study of intravitreal (IVT) EYE201 (Tiespectus) in participants with either diabetic macular edema (DME) or neovascular age-related macular degeneration (nvAMD).
Rivoli CRVO BP44241 [Enrollment Open]
A phase IB, Multicenter, Randomized, Double Masked, Active Comparator-Controlled Study to investigate the biological activity, safety, tolerability, pharmacokinetics and pharmacodynamics of ro7200394 in participants with macular edema secondary to central retinal vein occlusion
Brunello – Eyebio [Enrollment Open]
A randomized, double-masked, multi-center, 3-arm pivotal phase 2/3 study to evaluate the efficacy and safety of intravitreal EYE103 compared with intravitreal ranibizumab (0.5 mg) in participants with diabetic macular edema.
Thames – Genentech [Enrollment Open]
Phase I/II to evaluate the safety and tolerability, pharmacokinetics, and efficacy of RO7446603 administered alone or in combination with aflibercept or faricimab in patients with diabetic macular edema.
Rioja – Eyebio [Enrollment Open]
A phase 1/2a 2-part study consisting of an open-label multiple ascending dose (MAD) safety study in participants with macular edema following branch retinal vein occlusion (BRVO), and a dose-finding, double-masked, comparative safety and preliminary efficacy study of intravitreal (IVT) EYE201 (Tiespectus) in participants with either diabetic macular edema (DME) or neovascular age-related macular degeneration (nvAMD).
Barolo – Eyebio [Enrollment Open]
A randomized, double-masked, multicenter, 3-arm pivotal phase 2/3 study to evaluate the efficacy and safety of intravitreal EYE103 compared with intravitreal ranibizumab (0.5 mg) in participants with diabetic macular edema.
For study inquiries please contact:
Diana A. CCRC, COT
Senior Clinical Research Coordinator
[email protected]
713-357-4976